AC Immune SA is a biopharmaceutical company. It is engaged in leveraging its two proprietary technology platforms to discover, design and develop novel, proprietary medicines for treatment of neurodegenerative diseases.

AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company, which engages in leveraging two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. It's products include: crenezumab, humanized, monoclonal, conformation-specific anti-Abeta antibody that developed using the SupraAntigenâ¢ platform. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, and Andrea Pfeifer on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Should you buy, sell, or hold AC Immune SA (ACIU) ?

AC Immune SA (ACIU) : Buy or Sell